April Qing and rain suddenly clear, Nanshan when the door to turn clear. Since the establishment and operation of the new R&D center, Nanjing REGENECORE has further implemented the strategic planning of the development and research of antibody drugs and cell therapy. In order to better promote the research and development of REGENECORE, in April 2021, the leaders of the group visited Nanjing REGENECORE new research and development center for work guidance.

Professor Xie Wei, chief scientist of REGENECORE, and Wang Yang, general manager of REGENECORE attended the meeting. At the work guidance meeting, Wang Yang, general manager of Regenecore, reported the development of the company's staff and team in the first quarter of 2021 and the progress of the research and development work, focusing on the work progress of the company's first antibody drug project RC14/16, and further reported the company's research and development goals and plans in the second quarter of 2021.

In the first quarter of 2021, REGENECORE expanded its staff according to the overall plan of the company at the beginning of the year. At this work guidance meeting, Chairman Lv Xiangyang and the leaders of the group optimized the organizational structure of Regenecore and put forward new requirements for the research and development of Regenecore. Under the leadership of the group, REGENECORE goes down every step is solid and powerful. Every employee of REGENECORE will strive to make progress in the future work, and strive to achieve research and development results as soon as possible to generate income for the group!